(Circulation. 1995;92:31-38.)
© 1995 American Heart Association, Inc.
Articles |
Fibrinogen After Coronary Angioplasty as a Risk Factor for Restenosis
From the Department of Cardiology (G.M., G.D., Y.G., D.T.) and the Laboratory of Hemostasis (A.A.), Centre Hospitalier Universitaire Pitié-Salpétrière, and the Laboratory of Biophysics, Hôpital F. Widal (E.V.), Paris, France.
Correspondence to Gilles Montalescot, MD, PhD, Department of Cardiology, Centre Hospitalier Universitaire Pitié-Salpétrière, 47 boulevard de l'Hôpital, 75013, Paris, France.
Background Fibrinogen is a risk factor for cardiovascular disease and is related to the severity of coronary atherosclerosis. Its role in restenosis after coronary angioplasty remains unknown. Although platelets and thrombosis contribute to the pathogenesis of restenosis, few clinical data are available concerning the relations between restenosis and proteins of the coagulation and fibrinolytic systems.
Methods and Results In 107 consecutive patients undergoing coronary angioplasty, we measured plasma levels of tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor–1 (PAI-1), von Willebrand factor, and fibrinogen before and immediately after angioplasty and at a 6-month follow-up. The individual changes of intraluminal diameter were measured by quantitative coronary angiography, and patients were classified according to four definitions of restenosis: (1) a final stenosis >50%, (2) a loss of minimal luminal diameter during the follow-up period greater than the measurement variability in our laboratory (>0.52 mm), (3) a loss of at least 50% of the gain in luminal diameter achieved by angioplasty, and (4) the combination of definitions 1 and 2. The relations between coagulation variables and each definition of restenosis were assessed univariately; then with the clinical variables included, the relations were analyzed multivariately. Angiographic follow-up was obtained in 92% of patients with a primary success of angioplasty. Global restenosis rates were 38%, 43%, 48%, and 30% for definitions 1 through 4, respectively. Plasma levels of t-PA antigen and PAI-1 antigen were not associated with any of the four definitions of restenosis. Multivariate analysis demonstrated that von Willebrand factor measured immediately after angioplasty predicted restenosis according to definitions 2 and 3. Fibrinogen measured within 6 months of follow-up was significantly increased in all restenosis groups of the four definitions. Patients with a fibrinogen concentration >3.5 g/L at follow-up had higher restenosis rates than patients with a concentration <3.5 g/L: 55% versus 22% (P=.001), 68% versus 31% (P=.002), 63% versus 37% (P=.01), and 74% versus 26% (P=.002) for definitions 1 through 4, respectively. The loss index was lower (P=.003) and the net gain higher (P=.03) in patients with a fibrinogen level <3.5 g/L. There was a significant correlation between fibrinogen level and angiographic loss index (r=.41; P<.0001). Multivariate analysis confirmed that the fibrinogen level predicted restenosis with all definitions.
Conclusions An independent relation exists between von Willebrand factor measured immediately after angioplasty and restenosis defined by the degree of intraluminal renarrowing. An elevated fibrinogen level during follow-up is a strong biochemical predictor of restenosis. Therefore, fibrinogen should be considered at least as an independent marker of restenosis and perhaps as a common risk factor for both spontaneous coronary atherosclerosis and postangioplasty restenosis, which is an accelerated form of atherosclerosis.
Key Words: stenosis • angioplasty • fibrinolysis • von Willebrand factor • plasminogen activators
This article has been cited by other articles:
 |
|
 |
|
  G. Heper, S. N. Murat, T. Durmaz, and F. Kalkan Prospective Evaluation of von Willebrand Factor Release After Multiple and Single Stenting Angiology, March 1, 2004; 55(2): 177 - 186. [Abstract] [PDF]
|
|
|
|
 |
|
 B. M. Rahel, F. L.J. Visseren, M.-J. Suttorp, T. H.W. Plokker, J. C. Kelder, B. M. de Jongh, K.P. Bouter, and R. J.A. Diepersloot Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention Cardiovasc Res, October 15, 2003; 60(1): 136 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H Reinhart Fibrinogen - marker or mediator of vascular disease? Vascular Medicine, August 1, 2003; 8(3): 211 - 216. [Abstract] [PDF]
|
|
|
|
|
|
G. Heper and M. Bayraktaroglu The Importance of von Willebrand Factor Level and Heart Rate Changes in Acute Coronary Syndromes: A Comparison with Chronic Ischemic Conditions Angiology, May 1, 2003; 54(3): 287 - 299. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Meade, R. Zuhrie, C. Cook, and J. Cooper Bezafibrate in men with lower extremity arterial disease: randomised controlled trial BMJ, November 16, 2002; 325(7373): 1139 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chanda and C. C. Canver Reversal of preexisting vasospasm in coronary artery conduits Ann. Thorac. Surg., August 1, 2001; 72(2): 476 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, P. Villain, J.-M. Boulenc, M.-C. Morice, L. Maillard, M. Pansieri, et al. Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction N. Engl. J. Med., June 21, 2001; 344(25): 1895 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lafont, J. L. Dubois-Rande, P. G. Steg, P. Dupouy, D. Carrie, P. Coste, A. Furber, F. Beygui, L. J. Feldman, S. Rahal, et al. The French randomized optimal stenting trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography J. Am. Coll. Cardiol., August 1, 2000; 36(2): 404 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Cooke, G. M. Eaton, G. Whitby, R. A. Kennedy, P. F. Binkley, M. L. Moeschberger, and C. V. Leier Plasma atherogenic markers in congestive heart failure and posttransplant (heart) patients J. Am. Coll. Cardiol., August 1, 2000; 36(2): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Montalescot, J. P. Collet, L. Lison, R.e. Choussat, A. Ankri, E. Vicaut, K. Perlemuter, F. Philippe, G.e. Drobinski, and D. Thomas Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina J. Am. Coll. Cardiol., July 1, 2000; 36(1): 110 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Hojo, U Ikeda, T Katsuki, O Mizuno, H Fukazawa, K Kurosaki, H Fujikawa, and K Shimada Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis Heart, July 1, 2000; 84(1): 83 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C LE FEUVRE Angioplasty and stenting in patients with renal disease Heart, January 1, 2000; 83(1): 7 - 8. [Full Text] [PDF]
|
|
|
|
|
|
A. Buffon, G. Liuzzo, L. M. Biasucci, P. Pasqualetti, V. Ramazzotti, A. G. Rebuzzi, F. Crea, and A. Maseri Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1512 - 1521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Harjai Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen Ann Intern Med, September 7, 1999; 131(5): 376 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Faraggi, G Montalescot, L Sarda, J F Heintz, D Doumit, G Drobinski, I Sotirov, D Le Guludec, and D Thomas Spontaneous late improvement of myocardial viability in the chronic infarct zone is possible, depending on persistent TIMI 3 flow and a low grade stenosis of the infarct artery Heart, April 1, 1999; 81(4): 424 - 430. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. M. Tran, H. S. Paterson, W. Meldrum-Hanna, and R. B. Chard Tunnelling versus open harvest technique in obtaining venous conduits for coronary bypass surgery Eur. J. Cardiothorac. Surg., December 1, 1998; 14(6): 602 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Courtman, S. M. Schwartz, and C. E. Hart Sequential Injury of the Rabbit Abdominal Aorta Induces Intramural Coagulation and Luminal Narrowing Independent of Intimal Mass : Extrinsic Pathway Inhibition Eliminates Luminal Narrowing Circ. Res., May 19, 1998; 82(9): 996 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T Powell Vascular damage from smoking: disease mechanisms at the arterial wall Vascular Medicine, February 1, 1998; 3(1): 21 - 28. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Zito, A. Di Castelnuovo, C. Amore, A. D'Orazio, M. B. Donati, and L. Iacoviello Bcl I Polymorphism in the Fibrinogen ß-Chain Gene Is Associated With the Risk of Familial Myocardial Infarction by Increasing Plasma Fibrinogen Levels : A Case-Control Study in a Sample of GISSI-2 Patients Arterioscler. Thromb. Vasc. Biol., December 1, 1997; 17(12): 3489 - 3494. [Abstract] [Full Text]
|
|
|
|
|
|
M. Tschopl, D. A. Tsakiris, G. A. Marbet, K.-H. Labs, and K. Jager Role of Hemostatic Risk Factors for Restenosis in Peripheral Arterial Occlusive Disease After Transluminal Angioplasty Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 3208 - 3214. [Abstract] [Full Text]
|
|
|
|
|
|
J. Levenson, P. Giral, J. L. Megnien, J. Gariepy, M.-C. Plainfosse, and A. Simon Fibrinogen and Its Relations to Subclinical Extracoronary and Coronary Atherosclerosis in Hypercholesterolemic Men Arterioscler. Thromb. Vasc. Biol., January 1, 1997; 17(1): 45 - 50. [Abstract] [Full Text]
|
|
|
|
 |
|
 Elevated Fibrinogen Predicts Restenosis Journal Watch Cardiology, September 1, 1995; 1995(901): 4 - 4. [Full Text]
|
|